<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706507</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121219</org_study_id>
    <secondary_id>1UG3HL147011-01A1</secondary_id>
    <secondary_id>10547</secondary_id>
    <nct_id>NCT04706507</nct_id>
  </id_info>
  <brief_title>Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis</brief_title>
  <acronym>GRAIL^3</acronym>
  <official_title>Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 study designed to evaluate whether the administration of ganciclovir&#xD;
      increases ventilator-free days in immunocompetent patients with sepsis associated acute&#xD;
      respiratory failure. Our hypothesis is that IV ganciclovir administered early in critical&#xD;
      illness will effectively suppress CMV reactivation in CMV seropositive adults with&#xD;
      sepsis-associated acute respiratory failure thereby leading to improved clinical outcomes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days in immunocompetent patients with sepsis-associated acute respiratory failure</measure>
    <time_frame>up to 28 days</time_frame>
    <description>To evaluate whether administration of ganciclovir increases ventilator-free days in immunocompetent patients with sepsis-associated acute respiratory failure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">485</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>IV Ganciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg/kg IV twice daily for 5 days, then followed by IV ganciclovir once daily until hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline IV twice daily for 5 days, then followed by IV normal saline once daily until hospital discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Ganciclovir</intervention_name>
    <description>For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.</description>
    <arm_group_label>IV Ganciclovir</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cytovene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject/next of kin informed consent&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  CMV IgG seropositive by standard serologic methods&#xD;
&#xD;
          -  Intubated and requiring mechanical positive pressure ventilation with positive&#xD;
             end-expiratory pressure (PEEP) &gt; 5 cmH2O; PaO2/FiO2 &lt; 300mmHg; and new, or if no prior&#xD;
             imaging, presumed new unilateral or bilateral infiltrates on chest radiography&#xD;
             occurring in the setting of sepsis from any source&#xD;
&#xD;
          -  Meets criteria for sepsis within a 24-hour time period within the 120-hour screening&#xD;
             window after hospitalization). Sepsis will be defined according to the recent Sepsis-3&#xD;
             consensus definition (outlined briefly below and in more detail in Appendix G) [70]:&#xD;
&#xD;
               -  Infection suspected or confirmed by the treating physician and&#xD;
&#xD;
               -  Organ dysfunction measured as an acute change in total SOFA score &gt;2 points after&#xD;
                  the infection (baseline SOFA score assumed 0 unless known pre-existing organ&#xD;
                  dysfunction).&#xD;
&#xD;
          -  On the day of randomization (by local criteria):&#xD;
&#xD;
               -  Not eligible for SBT (Spontaneous Breathing Trial. Use of sedation and/or&#xD;
                  vasopressor does not specifically contraindicate SBT) Or&#xD;
&#xD;
               -  Failed SBT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected immunosuppression, including:&#xD;
&#xD;
               -  HIV+ (i.e. prior positive test or clinical signs of suspicion of HIV/AIDS; a&#xD;
                  negative HIV test is not required for enrollment)&#xD;
&#xD;
               -  stem cell transplantation:&#xD;
&#xD;
                    -  within 6 months after autologous transplantation or&#xD;
&#xD;
                    -  within 1 years after allogeneic transplantation (regardless of&#xD;
                       immunosuppression)&#xD;
&#xD;
                    -  greater than 1 year of allogeneic transplantation if still taking systemic&#xD;
                       immunosuppression or prophylactic antibiotics (e.g. for chronic graft versus&#xD;
                       host disease) Note: if details of stem cell transplantation are unknown,&#xD;
                       patients who do not take systemic immunosuppression and do not take&#xD;
                       anti-infective prophylaxis are acceptable for enrollment and randomization.&#xD;
&#xD;
               -  solid organ transplantation with receipt of systemic immunosuppression (any time)&#xD;
&#xD;
               -  cytotoxic anti-cancer chemotherapy within the past three months (Note:&#xD;
                  next-of-kin estimate is acceptable)&#xD;
&#xD;
               -  congenital immunodeficiency requiring antimicrobial prophylaxis (e.g. TMP-SMX,&#xD;
                  dapsone, antifungal drugs, intravenous immunoglobulin)&#xD;
&#xD;
               -  receipt of one or more of the following in the indicated time period (see&#xD;
                  Appendix C):&#xD;
&#xD;
                    -  within 6 months: alemtuzumab, antithymocyte/antilymphocyte antibodies, or&#xD;
                       other immunosuppressive drugs associated with CMV reactivation Note: if no&#xD;
                       information on these agents is available in the history and no direct or&#xD;
                       indirect evidence exists from the history that any condition exists that&#xD;
                       requires treatment with these agents (based on the investigator's&#xD;
                       assessment), the subject may be enrolled. For all drug information,&#xD;
                       next-of-kin estimates are acceptable. See Appendix C for commonly prescribed&#xD;
                       immunosuppressive agents. Information on the use of biologics with moderate&#xD;
                       immunosuppressive effect but no known effect on CMV are permitted and will&#xD;
                       be recorded in the CRFs.&#xD;
&#xD;
          -  Expected to survive &lt; 72 hours (in the opinion of the investigator)&#xD;
&#xD;
          -  Has been hospitalized for &gt; 120 hours (subjects who are transferred from a chronic&#xD;
             care ward, such as a rehabilitation unit, with an acute event are acceptable).&#xD;
&#xD;
          -  Pregnant or breastfeeding (either currently or expected within one month). Note: for&#xD;
             women of childbearing age (18-60 years, unless documentation of surgical sterilization&#xD;
             [hysterectomy, tubal ligation, oophorectomy]), if a pregnancy test has not been done&#xD;
             as part of initial ICU admission work-up, it will be ordered stat and documented to be&#xD;
             negative before randomization. Both urine and blood tests are acceptable.&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1,000/mm3 (if no ANC value is available, the WBC must be &gt;&#xD;
             2500/mm3)&#xD;
&#xD;
          -  Use of anti-CMV drugs (cidofovir, letermovir, foscarnet, valganciclovir, ganciclovir)&#xD;
             within seven (7) days of patient randomization.&#xD;
&#xD;
          -  Currently enrolled in an interventional trial of an investigational therapeutic agent&#xD;
             known or suspected to have anti-CMV activity or to be associated with significant&#xD;
             known hematologic toxicity (prior approval required).&#xD;
&#xD;
          -  At baseline patients who have both a tracheostomy, and have been on continuous 24-hour&#xD;
             chronic mechanical ventilation.&#xD;
&#xD;
          -  Patients with Child Class C Cirrhosis.&#xD;
&#xD;
          -  Patients with severe (requiring home oxygen) pre-existing interstitial lung disease.&#xD;
&#xD;
          -  Allergy to ganciclovir&#xD;
&#xD;
          -  Incarcerated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boeckh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Boeckh, MD</last_name>
    <phone>206 667 6706</phone>
    <email>mboeckh@fredhutch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Kimball, PhD,RN</last_name>
    <phone>206 667 2904</phone>
    <email>lkimball@fredhutch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ellen Burnham, MD</last_name>
      <email>Ellen.Burnham@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Needham, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca M Baron, MD</last_name>
      <email>rbaron@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Hyzy, MD</last_name>
      <phone>734-936-5201</phone>
      <email>rhyzy@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mayur Ramesh, MD</last_name>
      <email>Mramesh1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marin Kollef</last_name>
      <email>kollefm@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefioure Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Gong, MD, MS</last_name>
      <email>MGONG@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Cox, MD</last_name>
      <email>christopher.cox@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wakeforest University, School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clark Files, MD</last_name>
      <email>Clark.Files@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Hite, MD</last_name>
      <email>hitern@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abhijit Duggal, MD</last_name>
      <email>DUGGALA2@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Exline, MD</last_name>
      <phone>614-293-4925</phone>
      <email>Matthew.Exline@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Gunn, MD</last_name>
      <phone>412-958-8398</phone>
      <email>gunnsr@ccm.upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nandita Nadig</last_name>
      <email>nadig@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todd Rice, MD</last_name>
      <email>todd.rice@Vanderbilt.Edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samuel Brown, MD</last_name>
      <email>Samuel.Brown@imail.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Stapleton, MD</last_name>
      <email>renee.stapleton@med.uvm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajit Limaye, MD</last_name>
      <phone>206-598-1041</phone>
      <email>ALimaye@u.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajit Limaye, MD</last_name>
      <phone>206-598-1041</phone>
      <email>ALimaye@medicine.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine &amp; Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Loren C Denlinger, MD,PhD</last_name>
      <phone>608-261-1552</phone>
      <email>cd@medicine.wisc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Michael Boeckh</investigator_full_name>
    <investigator_title>Professor, Vaccine and Infectious Disease Division, Fred Hutch</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

